Brexpiprazole Study
Study Details
Study Description
Brief Summary
The proposed study is a 3-site, 12-week, novel, feasibility, investigation of patients who have co-occurring diagnoses of schizophrenia and current substance use disorder (alcohol, cocaine, heroin, or cannabis). Eighty patients will be randomly assigned to switch to brexpiprazole (the brexpiprazole group) or remain on the same antipsychotic treatment (the control group). The study will be conducted at 3 sites in the US. The investigators expect to enroll 80 subjects across 3 sites. UMass Medical School, Worcester MA is the lead site. Sub-sites include Massachusetts General Hospital (MGH) and the University of North Carolina at Chapel Hill (UNC).
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 4 |
Detailed Description
STUDY OBJECTIVES
The primary objectives of the study include:
-
examine the effect of brexpiprazole treatment on the number of days of substance use in the past week as measured by the Timeline Follow-Back (TLFB) assessment;
-
examine the effect of brexpiprazole treatment on substance craving using 100-mm visual analogue scale (VAS).
The secondary objectives are to examine the effect of brexpiprazole treatment on:
-
the dollar amount spent on substances in the past week;
-
the psychiatric symptoms as measured using PANSS
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Experimental Brexpiprazole 4mg daily for 12 weeks |
Drug: Brexpiprazole
Brexpiprazole 4mg daily for 12 weeks
Other Names:
|
| Active Comparator: Treatment as Usual Stay on current antipsychotic medication for 12 weeks |
Other: Treatment as Usual
Current antipsychotic medication for 12 weeks
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Time line Follow back (TLFB) [12 weeks]
A scale used to measure weekly substance use starting 30 days prior to the screening until the end of the 12-week study period. Measurement values for the scale vary based on substance used (i.e. alcohol = number of standard drinks/ day; Cannabis = number of joints/ day; cocaine and heroine = did you use this day), but for our purposes data collected will be reduced to whether or not a subject used on a particular day. For this study, a decrease in the number of days of substance use over a 7-day period will be considered an improved outcome.
- Visual Analog Scale [12 weeks]
measure to assess craving for substances. Subjects will make a mark on an unlabeled 100 millimeter line indicating their desire to use a particular substance over the past 7-days. A score of 0 indicates no desire to use and 100 indicating the strongest desire to use possible. This assessment will be taken on a weekly basis throughout the 12-week study. Every substance that a subject has a substance use disorder for will be measured separately. For this study a decreased score represents an improved outcome.
Secondary Outcome Measures
- Amount of money spent on substances [12 weeks]
The amount of money spent on substances over a 7-day period will also be recorded as part of each weekly visit. Decreased money spent on substances over a 7-day period will also be considered an improved outcome.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Age 18-65 years old
-
Meets the DSM-5 criteria for diagnoses of schizophrenia or schizoaffective disorder and substance use disorder (alcohol, cocaine, heroin, or cannabis) based on the Structured Clinical Interview for the DSM-5 (SCID)
-
Uses substance on at least 4 of the past 30 days prior to randomization with at least one use in the week prior to randomization for one of substances (cocaine, heroin, cannabis or alcohol) assessed by the TLFB interview
-
Stable dose of antipsychotic agent for at least one month
-
Well established compliance with outpatient medications
-
Female subjects of child-bearing potential are required to practice appropriate birth control methods during the study.
Exclusion Criteria:
-
Psychiatrically unstable
-
Currently meets DSM-5 criteria for any substance use disorder other than caffeine, nicotine, alcohol, cocaine, heroin and cannabis
-
Significant, unstable medical conditions including severe cardiovascular, hepatic, renal or other medical diseases
-
History of a seizure disorder
-
Pregnancy or breastfeeding
-
Currently on aripiprazole or cariprazine
-
Currently on medications to treat substance use (disulfiram, naltrexone, acamprosate,methadone, buprenorphine, varenicline or buproprion)
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Massachusetts General Hospital | Boston | Massachusetts | United States | 02114 |
| 2 | UMass Medical School | Worcester | Massachusetts | United States | 01655 |
| 3 | University of North Carolina | Chapel Hill | North Carolina | United States | 27599 |
Sponsors and Collaborators
- University of Massachusetts, Worcester
- Massachusetts General Hospital
- University of North Carolina, Chapel Hill
- Otsuka Pharmaceutical Co., Ltd.
Investigators
- Principal Investigator: Xiaoduo Fan, MD, University of Massachusetts, Worcester
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 14611